Prudo-Chlebosz Raymond
SEC CIK 1653262 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | Dir | 2.48M | — | — | 3 | 2024-05-31 | 2025-03-06 |
Most active insiders at AKTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Farag Kameel D. | Interim CFO | — | — |
| 2 | Patel Samir Rashmikant | Dir, 10% | — | — |
Prudo-Chlebosz Raymond made no open-market trades at AKTX in the last 12 months.
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-10 | 2025-03-06 | AKTX | Akari Therapeutics Plc | Prudo-Chlebosz Raymond | Dir | A - Grant | $1.12 | +446.4K | 2.48M | +22% | +$500.0K |
| D | 2024-12-03 | 2024-12-02 | AKTX | Akari Therapeutics Plc | Prudo-Chlebosz Raymond | Dir | A - Grant | $0.00 | +419.29M | 4.08B | +11% | $0 |
| D | 2024-06-04 | 2024-05-31 | AKTX | Akari Therapeutics Plc | Prudo-Chlebosz Raymond | Dir | A - Grant | $0.00 | +1.33B | 3.66B | +57% | $0 |
Purchase Sale Sale after option exercise All abbreviations